There are currently randomized controlled trials evaluating the efficacy of leronlimab, a CC chemokine receptor 5 (CCR5) modulator, in patients with mild to severe SARS-CoV-2–induced ARDS (clinicaltrials.gov, NCT04347239). This evidence concerns the gene CCR5 and acute respiratory distress syndrome.